LAUSANNE, Switzerland--(BUSINESS WIRE)--Second Sight® Medical Products, Inc., the leading developer of retinal prostheses for the blind, announced that it will increase patient enrollment for the ArgusTM II Retinal Implant study throughout clinical trials sites within Europe. The three-year feasibility study is currently underway in the United States, Europe and Mexico for people with Retinitis Pigmentosa (RP), a genetic eye disease that causes blindness.
